Home
About
Publications Trends
Recent Publications
Expert Search
Archive
pharmaceutical ingredients
What Are the Challenges in Developing Cancer Drugs?
Developing cancer drugs is fraught with challenges:
1.
Resistance
: Cancer cells can develop resistance to drugs, making treatment less effective over time.
2.
Side Effects
: Many cancer drugs have severe side effects, limiting their use.
3.
Complexity
: The diverse nature of cancer means that a drug effective for one type may not work for another.
4.
Cost
: The development and production of cancer drugs are expensive, affecting their accessibility.
Frequently asked queries:
What Are Pharmaceutical Ingredients in Cancer Treatment?
What Are Some Common Active Ingredients Used in Cancer Therapy?
What Role Do Inactive Ingredients Play?
How Are Pharmaceutical Ingredients Selected?
What Are the Challenges in Developing Cancer Drugs?
What Is the Future of Pharmaceutical Ingredients in Cancer Treatment?
What is the Role of RNA Markers in Prognosis?
What Is the Role of Multidisciplinary Care?
What Are Some Key DNA Repair Mechanisms?
What Types of Cancer are Associated with HHV-8?
Why are Spontaneous Reporting Systems Important in Cancer?
What is the Breakthrough Prize in Life Sciences?
What is Diagnostic Testing in Cancer?
What are the Treatment Options for Communication Disorders in Cancer Patients?
What are the Treatment Options for Stage I Cancer?
What Are Some Strategies to Reduce Anxiety in Cancer Patients?
Who are the Key Participants in the NCTN?
What Role Do Tumor Cells Play in MHC Class I Expression?
Are There Resources for Further Information?
When is Lumpectomy Recommended?
Top Searches
Brain Tumor
Breast cancer
cancer
Cancer Genomics
Chemotherapy
hepatocellular carcinoma
Lung Cancer
Nanotechnology
Non-Hodgkin’s Lymphoma
Radiation-Induced Malignancies
Follow Us
Facebook
Linkedin
Youtube
Instagram
Partnered Content Networks
Relevant Topics
4D Segmentation
Alopecia
Atlas-based Segmentation
Automated Segmentation
B-cell malignancies
biomarkers
Brain Tumor
Brain Tumor Segmentation
Breast cancer
cancer
Cancer Genome Atlas
Cancer genomics
Cancer treatment
CAR T-cell therapy
Carcinogenesis
cell adhesion
cell migration
chemotherapy
Chromatin remodeling genes
Chronic inflammation
CIAbimatoprost
Co-morbidity
Combination therapy
Copy number variations
cytokine release syndrome
Deep Learning
Diagnosis challenges
diffuse large B-cell lymphoma
DNA damage
docetaxel-cyclophosphamide
Drug delivery
epirubicin-cyclophosphamide
extracellular matrix
Fibrosis
Genetic alteration
Glioblastoma
Gold nanoparticles
Hepatocellular carcinoma
High Tumor
image-guided radiotherapy
Imaging Techniques
Immunosuppression
Immunotherapy
Integrative genomics
integrin inhibitors
Integrins
intensity-modulated radiation therapy
Keratinocyte
Lipid-based nanoparticles
liver cancer
long-term cancer risks
Lung cancer
Machine Learning
Magnetic Resonance Imaging
metastasis
methyltransferase
MRI
Multi-modal Imaging
Multidisciplinary care
Mutual exclusivity analysis
Nanoparticles
Nanotechnology
neoadjuvant radiotherapy
neurotoxicity
Next-generation sequencing
nnovative Biomarkers
Non-Hodgkin’s lymphoma
Novel Biomarkers for Brain Tumors
Novel Chemotherapy
Oncogenic transcription factors
oncological diseases
paclitaxel
Personalized medicine
Photobiomodulation therapy
Polymeric nanoparticles
portal vein tumor thrombus
Probabilistic Models
proton therapy
Radiation-induced malignancies
radiotherapy
refractory lymphoma
relapsed lymphoma
Risk factors
secondary cancer prevention
secondary cancers
Silver nanoparticles
stereotactic body radiation therapy
Targeted therapy
Tolerability
transarterial chemoembolization
Tuberculosis
tumor microenvironment
tumor progression
Voltage-gated sodium channels
Subscribe to our Newsletter
Stay updated with our latest news and offers related to Cancer.
Subscribe